Business Context and Reporting Period
Company: Alcon, Inc. (Swiss corporation, majority-owned subsidiary of Nestlé S.A.)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Three and nine months ended September 30, 2006
Filing Date: October 24, 2006
Alcon operates globally through two segments: Alcon United States and Alcon International. The company markets products in three categories: pharmaceuticals, surgical equipment/devices, and consumer eye care.
Key Financial Metrics
| Metric (in millions) | 3 Months Ended Sept 30, 2006 | 3 Months Ended Sept 30, 2005 | 9 Months Ended Sept 30, 2006 | 9 Months Ended Sept 30, 2005 |
|---|---|---|---|---|
| Sales | $1,203.8 | $1,071.1 | $3,671.7 | $3,313.6 |
| Gross Profit | $902.4 | $824.7 | $2,756.8 | $2,490.9 |
| Gross Margin % | 75.0% | 77.0% | 75.1% | 75.2% |
| Operating Income | $261.0 | $367.9 | $1,179.2 | $1,114.5 |
| Net Earnings | $232.1 | $295.8 | $993.4 | $870.3 |
| Diluted EPS | $0.76 | $0.95 | $3.21 | $2.79 |
| Cash from Operations (9mo) | $914.9 | $1,073.1 | ||
| Net Cash Position (Sept 30, 2006) |
Liquidity & Debt (as of Sept 30, 2006):
- Cash and Cash Equivalents: $1,176.8 million
- Total Debt: $952.2 million (Short-term: $896.7m; Long-term: $55.5m)
- Net Cash: $224.6 million
- Shareholders' Equity: $2,699.9 million
Material Changes vs. Prior Period
- Revenue Growth: Global sales increased 12.4% in Q3 and 10.8% for the nine-month period. Constant currency growth was 11.3% (Q3) and 11.2% (9 months), driven by volume growth in pharmaceuticals, surgical lenses (AcrySof IQ/ReSTOR), and consumer eye care.
- Impairment Charges: A significant non-cash impairment loss of $144.8 million was recorded in Q3 related to refractive product line assets ($125.7m in amortization of intangibles, $19.1m in cost of goods sold). This reduced operating income by 29.1% in Q3 compared to the prior year.
- Accounting Changes: Adoption of SFAS No. 123(R) for share-based compensation increased expenses by $16.4 million in Q3 and $65.8 million for the nine months, reducing net earnings.
- Legal Settlement: A $121.0 million payment was made in July 2006 to settle patent litigation with Advanced Medical Optics (AMO). Because $242.0 million had been previously accrued, this resulted in a $119.0 million pretax benefit to operating income for the nine-month period.
- Share Repurchases: The company spent $728.4 million to acquire treasury shares during the nine months ended September 30, 2006.
Guidance, Outlook, and Risks
- Outlook: Management expects full-year effective tax rates to be approximately 17% to 18%, assuming retroactive extension of the U.S. research and experimentation credit. R&D expenses are expected to increase in Q4 2006 due to project costs.
- Collaboration Update: A co-promotion agreement with Eli Lilly for Arxxant (oral medication for diabetic retinopathy) faces uncertainty as the FDA requested a new three-year clinical trial. Lilly is weighing the feasibility of continuing development.
- Market Risks:
- Currency: Significant exposure to foreign exchange fluctuations; a 10% decline in foreign exchange rates could decrease earnings before taxes by approximately $9.0 million.
- Interest Rates: Majority of debt is short-term floating rate; sensitive to rising rates.
- Legal: Ongoing patent challenges from generic manufacturers (Teva, Apotex) regarding Vigamox and Patanol.
- Unusual Items: The Q3 results were heavily impacted by the $144.8 million impairment charge and the $119.0 million litigation benefit, making year-over-year comparisons difficult without adjusting for these non-recurring items.
Investor Verification Checklist
- Impairment Details: Verify the specific assets written down in the refractive product line and the impact on future depreciation/amortization schedules.
- Share-Based Compensation: Confirm the full-year impact of SFAS No. 123(R) adoption on operating margins and net earnings.
- Litigation Resolution: Ensure no further liabilities remain regarding the AMO settlement and monitor the status of the Arxxant FDA trial requirements.
- Cash Flow Usage: Review the sustainability of the $728.4 million share repurchase program alongside dividend payments ($416.8 million) given the net cash position.
- Constant Currency Growth: Validate the 11.2% constant currency sales growth to assess organic performance independent of exchange rate volatility.